PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY TO EVALUATE THE EFFICACY AND SAFETY OF RAVULIZUMAB IN ADULT PARTICIPANTS WHO HAVE THROMBOTIC MICROANGIOPATHY ASSOCIATED WITH A TRIGGER

Registry ID

ALXN1210-TMA-315

Source registry

HEALTH_CANADA

Status

Closed

Phase

PHASE3

Study type

INTERVENTIONAL

Sponsor

ALEXION PHARMACEUTICALS INC

Start date

2022-03-16

Completion date

2023-10-27

Last update

2021-05-11

Conditions

• THROMBOTIC MICROANGIOPATHY

View on source registry